Innate Pharma price target lowered to $11 from $11.50 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Innate Pharma (IPHA) to $11 from $11.50 and keeps a Buy rating on the shares. The firm postponed the U.S. launch of IPH6101 to 2029 from previously estimated 2027 and EU launch to 2030 from 2028.